Repositorio Institucional de la Universidad de Oviedo

Presence and impact of antidrug antibodies (adas) to tremelimumab (t) or durvalumab (d) in the phase 3 himalaya study of unresectable hepatocellular carcinoma (uhcc).

Author:

Crysler, Oxana V.; Yarchoan, Mark; Furuse, Junji; Varela Calvo, María; (et al.)

Publication date:

2023

Descripción física:

p. 551-551

URI:

https://hdl.handle.net/10651/74582

ISSN:

0732-183X; 1527-7755

Patrocinado por:

AstraZeneca